nach oben

Erschienen in:

Open Access 23.03.2020 | Main topic

Takotsubo syndrome: between evidence, myths, and misunderstandings

verfasst von: L. Christian Napp, MD, Johann Bauersachs, MD, FESC, FHFA, FAHA

Erschienen in: Herz | Ausgabe 3/2020

Abstract

Takotsubo syndrome (TS) is an acute cardiac condition characterized by transient wall motion abnormalities mostly of the left ventricle. First described in 1990, TS has gained substantial attention during the past 15 years. However, the disease is still underdiagnosed. Prospective studies on TS are largely lacking, and the condition remains incompletely understood. In addition, significant misconceptions and misunderstandings are evident, contributing to potentially severe underestimation. Here, we review important aspects of TS with a focus on pitfalls, misinterpretations, and knowledge gaps considered important during diagnosis and management of the disease.

Supplementary References to Tables 1–6

Electronic supplementary material

The online version of this article (https://doi.org/10.1007/s00059-020-04906-2) contains the references to the tables. The article and additional material are available in the electronic full text archive at http://www.springermedizin.de/herz. You will find the additional material at the end of the article under “Supplementary Material”.

Takotsubo syndrome (TS) is an acute cardiac condition originally described in 1990 in a book chapter [1] and in 1991 in a Japanese journal article [2]. Of note, several publications before 1990 reported patients who very likely had TS [3], however, without using the name Takotsubo. Most TS patients suffer from rather acute chest pain and dyspnea, and about two thirds of patients have experienced a preceding trigger, which may be either an emotional event such as anger or grief or a physical incident such as trauma, surgery, or infection, or both [4]. Since 50% of patients have ST-segment elevation on the ECG and cardiac biomarkers are usually elevated to a relevant extent, many TS cases are diagnosed by cardiac catheterization originally performed for suspected myocardial infarction [5]. TS is characterized by transient wall motion abnormalities with hypo- or more often akinesia of midventricular and apical segments of the left ventricle (LV) as well as hypercontractile basal segments. However, atypical forms exist involving only midventricular, basal, or focal parts of the LV, constituting about 25% of cases. Left ventricular ejection fraction (LVEF) is often severely reduced, and LV end-diastolic pressure (LVEDP) markedly elevated, both of which reflect acute impairment of systolic and diastolic LV function [4, 6]. A hallmark of TS is an often rapid recovery of wall motion abnormalities within days to weeks, which needs to be demonstrated by imaging in order to finally diagnose the disease, unless the patient dies beforehand [7]. Taken together, TS represents a prototypical acute heart failure syndrome, although the initial clinical presentation mimics that of an acute coronary syndrome.

While TS remained largely unnoticed for approximately 10 years after the initial description, the condition has gained enormous attention over the past years (Fig. 1). TS is still considered to be underdiagnosed, with an underestimated risk and incompletely understood pathogenesis [8]. Importantly, numerous misunderstandings have emerged in the context of TS. This is in part due to a lack of knowledge resulting in unproven assumptions, and in part due to some erroneous messages from early reports. However, there is also a phenomenon of “ghost messages,” which are repeatedly re-featured in reviews, letters, and sometimes also original studies, despite already convincing evidence from the existing literature. In addition, owing to the relatively low incidence of the condition, a large number of single case reports was published massively outnumbering original studies (Fig. 1). This was very likely associated with a reporting bias, as predominantly “clear” cases were published that were in line with early reports. Overall, a misconception of the disease has evolved: TS is still widely considered a benign, transient, “self-healing” disease with an emotional trigger and “clean” coronary arteries, but without relevant complications. In clinical routine one can even hear opinions such as, “I suspected my patient was suffering from acute myocardial infarction, but after all it was only Takotsubo,” reflecting a significant underestimation. Already the title of the first official description (“Takotsubo-type cardiomyopathy due to multivessel spasm”) [1] contained the term “cardiomyopathy,” suggesting a rather chronic condition, for which no robust evidence exists. In contrast, TS is not a benign disease [9], is not uniformly preceded by an emotional trigger [4], and does not require “clean” coronary arteries (see below). Based on the available evidence on TS, the present review focuses on pitfalls, misinterpretations, and knowledge gaps considered important during diagnosis and management of the disease.

Nomenclature

Most newly described entities or therapies undergo a change in their name or abbreviation. Indeed, TS has been ascribed numerous different names, especially in early years. While the initial description used the term “Takotsubo-type cardiomyopathy” [1], many of the following publications used “Takotsubo cardiomyopathy,” “left ventricular apical ballooning syndrome,” “broken heart syndrome,” or “stress cardiomyopathy” instead, among others (Table 1). However, these names either suggest that only the left ventricle is affected, or that the heart is always “broken” (emotional trigger), or that TS is a cardiomyopathy, all of which are not generally true. In 2011, an analysis of published reports uncovered that already at that time, 75 individual names had been used for the same condition [10]. These names were accompanied by an equally confusing number of abbreviations. Accordingly, a substantial debate on the nomenclature emerged [10‐16], which was also related to different diagnostic criteria (see below). In recent times, most scientists and TS experts agree to use the term “Takotsubo syndrome,” abbreviated either as “TS” or “TTS.” The word “Takotsubo” is a metaphor for the apical type of TS, where the shape of the LV during systole resembles a pot (Jap. tsubo) used to trap octopods (Jap. tako) in Japan. Even though it is not intuitive to use it for atypical TS types, the metaphor takotsubo prevents confusion and appreciates the pioneering work of Japanese researchers [10]. While some reports used a hyphenated version (“Tako-tsubo”), the nonhyphenated version is much more frequently used: Until 2 January 2020, Medline contained 616 publications with “Tako-tsubo” as a title word and 3062 publications with “Takotsubo” in the title.

Table 1

Takotsubo synonyms

Synonym (abbreviation)
Ampulla cardiomyopathy
Apical ballooning syndrome (ABS)
Left ventricular apical ballooning syndrome (LVABS)
Transient apical ballooning syndrome
Transient cardiac ballooning
Transient left ventricular apical ballooning (TLVAB)
Takotsubo cardiomyopathy (TC, TTC, TCM)
Takotsubo-like cardiomyopathy
Takotsubo cardiomyopathy syndrome
Takotsubo stress cardiomyopathy
Takotsubo syndrome (TS, TTS)
Stress cardiomyopathy (SCM)
Stress-induced cardiomyopathy
Broken heart syndrome

An overview of many more and also rarely used names for TS has been published elsewhere^S1

References to the tables are provided as electronic supplementary material

Documentation of recovery of TS-related wall motion abnormalities, i.e., normalization of systolic LV function in most patients, is required to diagnose TS across all types of diagnostic criteria (see below). Indeed, the often fast recovery of systolic LV function is a hallmark of TS and frequently astonishes treating physicians who had just encountered severe systolic dysfunction in their patients. This led to the assumption that TS is a “transient” disease and contributed to the misconception that the associated risk would be very low. Although there is new evidence that a TS episode results in subtle myocardial damage (see below), the term “cardiomyopathy” seems inappropriate [12] since to date there is no proof that relevant myocardial damage occurs. In contrast, the term “syndrome” better describes a condition that is incompletely understood, is probably not only a cardiac disease, and occurs in different settings. To date, it still remains unclear whether TS is a cardiac or extracardiac disease. The substantial incidence of TS in patients with extracardiac conditions such as pheochromocytoma, acute cerebral pathologies, and after administration of sympathomimetic drugs suggests that TS could be an end-organ epiphenomenon of an extracardiac disorder. Thus, overall it seems most meaningful to generally use the term “Takotsubo syndrome” for all typical and atypical TS forms.

Spasm, catecholamines, gender, and the brain

Initially, TS had been associated with macrovascular coronary spasm, as already reported in the first description of the disease [1, 2]. Several authors described either spontaneous or provoked spasm in TS patients [17]. However, wall motion abnormalities in TS are usually not congruent with the perfusion territory of an epicardial coronary artery, and therefore it appears rather unlikely that spasm in larger arteries is the cause of TS. This, however, does not exclude that spasm in smaller vessels, i.e., in arterioles, would be a key step during the development of TS.

In 2005, a pioneering study found higher levels of circulating catecholamines in TS patients as compared with age- and gender-matched patients with ST-segment elevation myocardial infarction (STEMI; [18]), suggesting that TS might be induced by a catecholaminergic surge. Although the sample size in that study was rather small, it gave the initial spark for research and recognition of the disease, which lasts until today (Fig. 1). However, subsequent studies had conflicting results [19‐21], leaving the question of whether or not TS is essentially associated with increased levels of circulating catecholamines largely unanswered. Thus, the debate on circulating catecholamine levels is ongoing [22]. Still, local myocardial catecholamine effects may be essential for stunning irrespective of circulating catecholamine levels. Many case reports have been published describing TS onset early or immediately after catecholamine administration [23]. However, compared with the high number of patients receiving catecholamines worldwide, the incidence of TS is still inadequately low, rendering catecholamine administration a trigger rather than a causative step. It is tempting to assume that coronary arteriolar spasm mediated by catecholamines induces TS. Importantly, spasm may also be a symptom demonstrating the catecholamine surge, i.e., rather be an epiphenomenon. The Mayo Clinic Diagnostic Criteria excluded pheochromocytoma as a cause of TS [24, 25], but there is no characteristic phenotypic difference between apical ballooning in pheochromocytoma and “classic” apical TS. The TS-like acute cardiac dysfunction in patients with pheochromocytoma is therefore no longer considered a different condition [7]. It should instead be considered a secondary form of TS, with pheochromocytoma as the trigger [16]. In turn, coexisting pheochromocytoma should be remembered and ruled out in TS patients with hypertensive emergency or shock.

Generally, some kind of sympathetic surrounding, either of endogenous or exogenous origin, is considered essential during TS development. However, this does not necessarily require an identifiable “stressor.” If an emotional or physical trigger is not present despite extensive history taking, there may still be a hidden source of stress or an unnoticed sympathetic surge. Notably, it is unknown how the characteristic wall motion abnormalities in TS develop. An animal study with rats has proposed a model in which differential beta-receptor signaling in basal and apical cardiomyocytes is responsible for the apical TS phenotype [26]. The concept behind this study appears very attractive for explaining the coexistence of basal hypercontraction and midventricular and apical hypo- and akinesia in the same heart. However, atypical forms of TS cannot be explained with this model, and there are many published reports of patients who had two, three, or even more episodes with different TS forms over time (see below), practically excluding that the proposed model is the primary explanation for the cardiac TS phenotype. Overall, albeit there is a “typical” association, from a mechanistic point of view catecholamines and sympathomimetic substances can neither be considered essential nor sufficient for TS development, and the debate is ongoing.

TS has also been proposed to be a special form of acute coronary syndrome (ACS). Troponin levels are elevated in virtually all TS patients, although levels are usually inappropriately low compared with the often severe systolic dysfunction of the LV. TS is characterized by the absence of substantial late gadolinium enhancement on cardiac magnetic resonance imaging (MRI, see below), which is an essential difference to ACS [27]. Therefore, ischemic myocardial necrosis does not explain wall motion abnormalities in TS. Of note, myocardial dysfunction may also be caused by ischemia without occurrence of necrosis, as ischemia is generally able to result in severe stunning of the heart [28]. Nuclear tests support this hypothesis, as perfusion is moderately reduced but metabolism strongly impaired in stunned myocardial segments in TS [29].

Occasionally, TS has been reported to occur in close relatives or siblings [30, 31]. Although TS is supposed to be nonhereditary, it is very likely that a genetic basis for susceptibility to triggers and sympathetic surroundings exists [32]. This preexisting vulnerability would further explain, at least in part, the recurrence of TS. The anecdotally described concurrent onset of TS in close relatives illustrates that there must be some biological background that in conjunction with an external trigger finally results in development of TS. Genetic studies have already identified promising loci, copy number variations, and polymorphisms in TS patients [33‐39]; however, these results require further confirmation and exploration before allowing for mechanistic conclusions.

Another key toward understanding the pathogenesis of TS might be hidden in the striking gender preponderance: 90% of patients are women, and of those 80% are postmenopausal. This led to the hypothesis that estrogen is a relative protective hormone, and that its decline may predispose individuals to TS development. In rats, estrogen supplementation attenuates the cardiac phenotype of immobilization stress [40, 41], and estrogen levels in patients with subarachnoid hemorrhage and LV dysfunction are lower than in those with normal systolic LV function [42]. Estradiol protects cardiomyocytes from isoproterenol-induced ROS-production and action potential duration prolongation [43]. In a recent study, women with TS and women matched for age and gender with STEMI had comparable levels of several sex hormones [44]. However, this study lacked a healthy control group. Furthermore, it is questionable whether measurement of circulating sex hormones at a single timepoint during the acute phase of the disease sufficiently reflects the complex sex hormone network. An earlier study found lower estradiol levels in TS patients than in STEMI patients or healthy controls [45]—acutely as well as at 6 years’ follow-up. Interestingly, glucose metabolism in the adult heart has strong sex preferences [46], which points toward cellular metabolism as an important sex-dependent factor during TS pathogenesis. Overall there remains much room for further research in order to understand the gender differences in TS.

TS is not rare in patients with acute neurological conditions, and in turn the prevalence of neurological disease in TS is higher than expected by random chance. In total, 50% of patients with TS suffer from an acute or chronic neurological or psychiatric disease [4], which suggests that the brain may be a critical component during pathogenesis. A recent study showed characteristic activity of brain regions in functional MRI [47], which may be the basis for future research to identify specific changes of regional brain function potentially inducing myocardial stunning. As outlined above, a “humoral” hypothesis postulates that circulating catecholamines, sex hormones, and others finally induce or trigger TS. Interestingly, reports of TS in patients after heart transplantation are extremely rare [48‐50], supporting the notion that an anatomical brain–heart axis may usually be required for development of TS. Overall, there is much room for innovative studies on the interaction of brain and heart in TS.

Age and trigger

Initially TS was mainly reported in postmenopausal women. Indeed, most patients with TS are female. In large registries the mean age is approximately 68 years, with 90% being women. However, over time many cases of TS were reported in men, and also in very young [51] and very old patients (Table 2). The youngest reported patient is a 9-day-old preterm infant, and the oldest one a 101-year-old woman. This demonstrates that TS should be considered a potential diagnosis across all genders and ages.

Table 2

The age spectrum of takotsubo syndrome

Study	Year	Sex	Age	Reported trigger	TS type
Rozema et al.^S2	2016	Female	9 days (born premature at 27.6 weeks’ gestation)	Unknown	Apical
Greco et al.^S3	2011	Male	2 days	Fetal distress, hypoxia	Apical^a
Hernandez et al.^S4	2010	Male	16 months	Cyclic vomiting	Apical
Schoof et al.^S5	2010	Female	2 years	Surgery	Apical
Maruyama et al.^S6	2006	Female	32 months	Buprenorphine and midazolam withdrawal	Apical
Fabi et al.^S7	2013	Female	4 years	Abdominal pain, fever, diarrhea	Apical
Otillio et al.^S8	2014	Female	6 years	Hemophagocytic lymphohistiocytosis	Apical
Berton et al.^S9	2012	Female	12 years	Spinal surgery, resuscitation	Apical
Srivastava et al.^S10	2016	Male	14 years	Prolonged seizure, after 6 months TS recurrence, again after seizure	Apical
Zalewska-Adamiec et al.^S11	2018	Female	15 years	Emotional distress	Apical
Ohwada et al.^S12	2005	Female	17 years	Hypoglycemia, anorexia	Apical
Okwechime et al.^S13	2018	Female	26 years	K2 synthetic marijuana abuse	Apical
An estimated 70% of patients are postmenopausal women with a mean age of 65–70 years
Singh et al.^S14	2012	Female	89 years	Grief	Apical
Xu et al.^S15	2012	Male	90 years	Pneumonia	Apical
Budnik et al.^S16	2015	Female	98 years	Chronic emotional stress	Apical
Zalewska-Adamiec et al.^S17	2016	Not reported	100 years	Not reported	Not reported
Bonfanti et al.^S18	2018	Female	101 years	Emotional distress	Apical

References to the tables are provided as electronic supplementary material

TS takotsubo syndrome

^aLikely apical TS, but TS type cannot be finally determined from the reported information in this case

From the beginning, TS was reported to be preceded by emotional triggers such as anxiety, fear, depression, or grief. Later on, awareness of physical triggers such as sepsis, trauma, surgery, acute intracerebral conditions, respiratory distress, bleeding, or diarrhea emerged. Importantly, emotional triggers may also be positive ones such as immense joy or achievements, also termed “happy heart syndrome” [52]. Of note, in some patients a physical trigger also serves as an emotional one, e.g., when physical trauma is associated with pain and fear, and in these patients it is virtually impossible to distinguish the finally leading trigger. Most importantly, and in contrast to early reports, around 30% of patients have no identifiable trigger [8], demonstrating that a trigger is not required to diagnose TS. This is also reflected by the current InterTAK Diagnostic Criteria. Comprehensive overviews of reported triggers of TS have been published elsewhere [53, 54]. The frequently reported triggers may at least in part be subject to a reporting bias: Many patients with acute cardiovascular conditions such as hypertensive emergency, intracranial hemorrhage, or myocardial infarction also experience preceding triggers [55]. In addition, emotional or physical stress alone is probably not sufficient to induce TS: Given the abundance and currently high level of emotional stress in everyday life, the incidence of TS is inadequately low. One study concluded that the preexisting personality in TS patients provides susceptibility to TS, suggesting that coping mechanisms and an individually increased response to stress finally drive the onset of TS [56]. However, TS development in nonawake patients is not sufficiently explained by a psychosomatic model. The interplay between triggers, the adrenergic system, and the cardiac phenotype as a “response” are likely too complex for a simple linear explanation.

Coexisting coronary artery disease

From the beginning, TS has been associated with the absence of coexisting coronary artery disease (CAD). In the first version of the Mayo Clinic Diagnostic Criteria, the presence of CAD with relevant stenoses was a rule-out criterion for the diagnosis of TS. Since apical TS was the only known form of TS at that time, the presence of CAD especially in the left anterior descending artery (LAD) often resulted in diagnosing an ACS instead. Magnetic resonance imaging (MRI) was not routinely available, hence there was no reliable measure to distinguish between ACS and TS. The recent consensus diagnostic criteria for TS allow for diagnosing TS in the presence of CAD (please see below). In contrast to the initial view that TS and obstructive CAD are contradictory, available data suggest that CAD is not rare in TS patients (Table 3; [57‐62]). However, published studies on CAD and TS are rather small, especially the investigated cohorts of patients with TS and coexisting obstructive CAD. Moreover, these studies reported only few details on the nature of CAD, and therefore further studies are urgently needed. Coronary imaging studies, using either intravascular ultrasound or optical coherence tomography, again demonstrated that CAD might be present, but conflicting findings regarding coronary culprit lesions do not allow for definitive conclusions [58, 63‐65]. Furthermore, ACS and TS can coexist [66‐72], thus making the correct diagnosis may sometimes be challenging, at least without cardiac MRI (see below).

Table 3

Takotsubo syndrome and coronary artery disease

Study	Year	Origin	TS patients	Normal coronary arteries	Nonobstructive CAD	Obstructive CAD
Haghi et al.^S19	2007	Germany	4	–	–	4 (100%)
Winchester et al.^S20	2008	USA	31	12 (38.7%)	10 (32.3%)	9 (29.0%)
Kurisu et al.^S21	2009	Japan	97	Not reported	Not reported	10 (10.3%)
Hoyt et al.^S22	2010	USA	97	16 (16.5%)	81 (83.5%)	13 (13.4%)
Haghi et al.^S23	2010	Germany	10	5 (50.0%)	2 (20.0%)	3 (33.3%)
Pawlowski et al.^S24	2010	Poland	14	–	14 (100%)	–
Delgado et al.^S25	2011	USA	11	–	11 (100%)	–
Parodi et al.^S26	2013	Italy	450	315 (70.0%)	92 (20.4%)	43 (9.6%)
Bill et al.^S27	2017	Germany	114	Not reported	Not reported	22 (19.3%)

References to the tables are provided as electronic supplementary material

CAD coronary artery disease, TS Takotsubo syndrome

A retrospective angiographic study of 109 TS patients found that tortuosity of coronary arteries and a “wrap-around” LAD are significantly more prevalent in TS patients than in age- and gender-matched control patients [73]. The study has limitations since patients with TS and coexisting CAD were not included and the control group had no CAD. Nevertheless, it might be worth studying whether anatomical variants and morphological characteristics of coronary arteries play a role in TS, either in the pathogenesis or as a disease modifier.

A very characteristic angiographic finding in TS is coronary slow-flow, especially in the LAD in patients with apical TS [74]. This might be attributed to microvascular dysfunction [75, 76], and its extent potentially correlates with adverse prognosis [77].

How to diagnose Takotsubo syndrome

Since 2003, several diagnostic criteria have been proposed (Table 4). Of these, the most widely used criteria have been the revised version of the Mayo Clinic Diagnostic Criteria, which were published in 2008 [25]. With different criteria considerable confusion and debate emerged, especially whether patients with CAD, pheochromocytoma, without triggers, and without ECG changes should be classified as having TS [78‐80]. The InterTAK diagnostic criteria ([7]; Table 5) are the most recent criteria, were agreed upon by most international leading TS investigators, and are largely congruent with the criteria published by the Taskforce on TS of the Heart Failure Association of the European Society of Cardiology [81]. The InterTAK Criteria further represent a modified and more precise version of the revised Mayo Clinic Diagnostic Criteria [25].

Table 4

Takotsubo syndrome diagnostic criteria

Year	Publication	Criteria
2003	Abe et al.^S28	Abe criteria
2004	Bybee et al.^S29	Mayo Clinic Diagnostic Criteria
2007	Kawai et al.^S30	Japanese diagnosis guidelines
2008	Prasad et al.^S31	Mayo Clinic Diagnostic Criteria, revised
2011	Omerovic^S32	Gothenburg criteria
2012	Wittstein^S33	Johns Hopkins criteria
2013	Redfors et al.^S34	Gothenburg criteria, revised
2014	Parodi et al.^S35	Takotsubo-Italian Network Proposal
2014	Madias^S36	Madias criteria
2014	Redfors et al.^S37	Gothenburg criteria, proposed new criteria
2016	Lyon et al.^S38	ESC Heart Failure Association Taskforce Criteria
2018	Ghadri et al.^S39	InterTAK Criteria

References to the tables are provided as electronic supplementary material

ESC European Society of Cardiology

Table 5

2018 InterTAK Diagnostic Criteria for Takotsubo Syndrome

1.	Transient LV dysfunction^a (hypokinesia, akinesia, or dyskinesia) presenting as apical, midventricular, basal, or focal ballooning. RV involvement can be present. Transitions between types can exist. Wall motion abnormalities usually extend beyond the perfusion territory of a single epicardial coronary artery, but rare exceptions can exist (focal TS)
2.	Emotional and/or physical triggers may precede onset of TS (not mandatory)
3.	(Acute) neurologic disorders or pheochromocytoma may serve as triggers for TS
4.	New ECG abnormalities (ST-segment elevation, ST-segment depression, T‑wave inversion, and QTc prolongation). Rare cases without any ECG changes exist
5.	Moderate elevation of troponin and creatine kinase and commonly significant elevation of BNP
6.	Presence of CAD does not preclude diagnosing TS
7.	Patients have no evidence of infectious myocarditis^b
8.	Postmenopausal women are predominantly affected

InterTAK Criteria shortened and adapted from the International Expert Consensus Document on Takotsubo Syndrome (Part I)^S39

References to the tables are provided as electronic supplementary material

CAD coronary artery disease, LV left ventricular, RV right ventricular, TS takotsubo syndrome

^aDocumentation of recovery of wall motion abnormalities is required for diagnosing TS, however wall motion abnormalities may remain for a prolonged period of time. Death before documentation of recovery is an important exception, in this case TS may be diagnosed also without documentation of recovery

^bCardiac magnetic resonance imaging is recommended to exclude infectious myocarditis and confirm diagnosis of TS

In clinical practice, it is often easy to diagnose TS, e.g., when a 70-year-old female patient with chest pain and ST-segment elevation undergoes coronary angiography, with angiographic absence of CAD and a typical apical ballooning pattern of the LV with basal hypercontraction. If wall motion abnormalities recover, TS can be finally diagnosed. However, frequently TS is suspected in patients with CAD or secondary to another severe comorbidity. Furthermore, it may at times be difficult to distinguish TS from myocarditis, ACS, or myocardial infarction with nonobstructive coronary atherosclerosis (MINOCA). Therefore, a pathway of meaningful clinical and technical investigation is required beyond diagnostic criteria, in order to make the correct diagnosis. Here, we propose a diagnostic pathway (Fig. 2), which covers the most important differential diagnoses to TS. Echocardiography is a cornerstone during diagnostic assessment, for which TS-specific aspects and recommendations have been published [82].

Echocardiographic examination should include assessment of LVEF, longitudinal strain, and wall motion abnormalities, in order to determine the TS type and the extent of LV dysfunction. Especially the focal type, which typically involves antero- or posterolateral segments of the LV, easily escapes echocardiographic standard views. Furthermore, echocardiography should screen for potential complications of TS, such as LV outflow tract obstruction (LVOTO), mitral regurgitation, and LV thrombus (Table 6).

Table 6

Echocardiography in Takotsubo syndrome

Parameters and potential pathological findings
LV	Systolic function, semiquantitative assessment
	LVEF (%)
	Wall motion abnormalities, TS type
	LV thrombus
	E/e’ (estimate of diastolic function)
	Global longitudinal strain
	LVOTO (mean gradient, mmHg)
RV	Systolic function, semiquantitative assessment
RV	RV involvement
Mitral regurgitation
SAM phenomenon of the anterior mitral leaflet
Coronary flow in the distal LAD^a
Ventricular septal rupture
Ventricular wall rupture
Pericardial effusion
Pleural effusion

Adapted from a more detailed description of echo findings and parameters^S40

References to the tables are provided as electronic supplementary material

LAD left anterior descending coronary artery, LV left ventricle, LVEF LV ejection fraction, LVOTO LV outflow tract obstruction, RV right ventricle, SAM Systolic anterior movement, TS Takotsubo syndrome

^aPresence of flow in the distal LAD on echocardiography is not a sufficient substitute of coronary angiography, but is of interest in patients without ST-segment elevations and apical ballooning

Coronary angiography should be performed according to current ACS guidelines [83, 84]. Patients with TS usually present acutely with symptoms of ACS, and approximately 50% of patients have ST-segment elevation on ECG. In addition, patients admitted to hospitals for noncardiac reasons, who develop TS during hospitalization, are often identified by signs or symptoms of heart failure and shock or by arrhythmia or cardiac arrest. Nearly all patients finally diagnosed with TS have a significant rise in troponin levels, and coronary angiography would therefore be indicated according to current ACS guidelines. Thus, there are good reasons for invasive angiography in adult patients suspected of suffering from TS, even if coronary computed tomography is sometimes recommended in patients with suspected TS. Today, many interventional cardiologists do not routinely perform ventriculography in patients with suspected ACS. Of note, there are no robust data demonstrating that ventriculography is unsafe, unless performed in predictably dangerous scenarios such as LV thrombus, very high LVEDP, infective aortic valve endocarditis, or severe renal failure. In contrast, ventriculography offers a unique chance to investigate LV wall motion and its relation to coronary anatomy and pathology [85]. Furthermore, in clinical practice there might be a delay between admission and echocardiography, and TS wall motion abnormalities may have already partly recovered after 2–3 days [86]. Thus, operators who continue to employ ventriculography (unless contraindicated) might see more cases of TS in patients with signs and symptoms of ACS, and are further able to measure end-diastolic LV pressure and a potential LV outflow tract gradient early.

In many patients with suspected TS, differential diagnoses such as ACS or myocarditis cannot be finally ruled out by echocardiography and coronary angiography findings. This is the case in patients where wall motion abnormalities are rather congruent with the perfusion territory of a diseased coronary artery, or in patients where wall motion is abnormal in posterolateral segments, where myocarditis frequently manifests. In these cases, cardiac MRI adds essential information for making the correct diagnosis [87], as all the aforementioned major cardiac conditions are associated with distinct findings in cardiac MRI [27, 88‐90]. Although not routinely used in all cardiac intervention centers, the availability and use of cardiac MRI will strongly increase over the next few years, and thereby contribute to enhancing accuracy and to avoiding misdiagnosis of cardiac conditions.

Most importantly, recovery of TS-related wall motion abnormalities is essentially required to finally diagnose TS, and especially in patients without early recovery, cardiac MRI should be considered.

Incidence

TS is probably still an underdiagnosed condition. An estimated 1–3% of patients presenting to hospitals with ACS symptoms are finally diagnosed with TS. However, with dedicated imaging early after admission the number of diagnosed TS cases is probably higher, since in some patients recovery of wall motion abnormalities may occur before echocardiography is performed. Therefore, it is very important to search for wall motion abnormalities especially in patients presenting as ACS but without coronary culprit lesions (Fig. 2), with the intention not to miss underlying TS. However, TS may also concur in patients with a major leading cardiovascular condition such as myocardial infarction or pulmonary embolism [66‐68, 70, 91, 92]. Thus, careful imaging is required also in presumably “clear” cases. Furthermore, TS might be an explanation for some unexplained cases of sudden death [93], but it is likely difficult to make a postmortem diagnosis [94].

Since the onset of TS is frequently associated with preceding stress from various sources, it appears reasonable that critically ill patients develop TS as a secondary disease. Indeed, the incidence of TS in critical care units in observational studies is substantial and higher than expected [95‐98]. Therefore, TS should be suspected in patients with unexplained heart failure, hypotension, shock, arrhythmia, or troponin elevation, and dedicated echocardiography should be performed. In the acute phase differential diagnosis should also take into account myocarditis and MINOCA (Fig. 2), both of which are likely underdiagnosed, too, and may require MRI or endomyocardial biopsy for making a definitive diagnosis.

Types of TS

The “classic” and most frequent TS type is LV apical ballooning, which is characterized by midventricular and apical stunning, accompanied by basal hypercontraction (Fig. 3). Sometimes a tiny strictly apical portion of the LV is hypercontractile in apical TS, which has been referred to as the apical “nipple” sign [99]. Observing an apical nipple sign is helpful if TS needs to be distinguished from suspected transient LAD occlusion, since a positive nipple sign makes the latter very unlikely, if the LAD perfuses the hypercontractile nipple. There is no clear agreement on how to distinguish apical TS with an apical nipple sign from midventricular TS, if the nipple sign comprises a larger apical area.

Nonapical TS types have been described, which account for an estimated 25–30% of cases and may be more frequently diagnosed in the future since awareness of atypical TS types is increasing. The midventricular TS type is characterized by midventricular stunning with basal and apical hypercontraction [100‐103], and is likely more frequent than currently assumed [104]. The basal type appears like a counterpart to the apical type, with basal stunning and midventricular and apical hypercontraction [105, 106]. The focal type occurs with focal stunning, most frequently in anterolateral or posterolateral segments [107, 108], and is often found with the most preserved LVEF and lowest complication rate of all types [104]. According to data from the InterTAK Registry, the TS type is not associated with clinical outcomes after adjusting for confounders [109]. However, there is a trend toward a worse prognosis with apical and basal and a better outcome with focal TS, respectively. There has been some confusion about the terms “inverse” and “reverse” TS, with the former describing basal and the latter describing midventricular TS. These terms should be avoided, as they are not unequivocal. Instead, basal and midventricular TS are the preferred designations. Basal TS is a common type in patients with subarachnoid hemorrhage, pheochromocytoma, and catecholamine administration. Therefore, such deleterious triggers should be ruled out once basal TS is diagnosed. Many cases of midventricular TS were published in the context of acute pulmonary triggers. Interestingly, in the literature nearly all children had an apical TS type (Table 2), the reason for which remains unknown. Recently, a fifth variant of TS was proposed, which is characterized by midventricular hypercontraction and basal and apical stunning [110]. However, confirmation of this phenotype by other cases and additional cardiac imaging is needed.

Right ventricular (RV) involvement is present in about 15% of cases [82], and isolated RV TS has been reported [111‐113]. In clinical practice, the RV is unfortunately still somewhat neglected and RV dysfunction is underestimated. RV failure carries a profound risk for patients with heart failure, also in TS [114]. In the context of TS, RV failure is understudied and frequently overlooked. It is especially unknown whether all TS types have the same frequency of RV involvement, and whether RV involvement mirrors the types of LV involvement. Generally, once TS is suspected in a patient, the echocardiographic examination should also investigate the RV in particular (Table 6).

In-hospital complications

Early reports suggested that TS is a transient disease with a very favorable prognosis. Indeed, some patients are admitted with severe chest pain and have rather severe LV dysfunction, but see a rapid recovery of LV function without arrhythmia, shock, or other complications. This is frequently the case in older female patients with emotional triggers, but only reflects a smaller part of the large spectrum of TS. In fact, the in-hospital phase is characterized by severe and frequent complications, which has been demonstrated by many groups from different continents [4, 9, 115, 116]. Beyond subgroups defined by age, trigger, TS type etc., a classification of primary and secondary TS has been proposed [81, 117], to account for differences in management and prognosis. Of note, patients admitted with ACS symptoms and finally diagnosed with TS (primary TS) have a better outcome than patients admitted for other reasons, in whom TS occurs later during hospitalization (often secondary TS; [118]). Thus, awareness should not only be directed at diagnosing TS in patients with ACS symptoms, but also in patients hospitalized for other reasons, who later develop signs or symptoms of TS such as chest pain, heart failure, shock, arrhythmia, ECG signs of ischemia, or syncope. In addition, in-hospital monitoring should not be omitted in both primary and secondary TS, as the incidence of acute complications is comparable to those with acute myocardial infarction [119]. If a patient with signs and symptoms of ACS undergoes coronary angiography and is diagnosed with apical TS instead, discharge on the next day (because “it is only TS”) is very likely too early and carries significant risk. The incidence of shock, resuscitation, and death is comparable to that in age- and gender-matched patients with ACS [4]. Selected patients might be candidates for a wearable defibrillator until recovery of LV wall motion abnormalities [120‐122].

Cardiogenic shock occurs in around 10% of patients with TS. However, in comparison to shock from myocardial infarction or myocarditis, some specific characteristics are present: Given the special role of catecholamines during pathogenesis, catecholamines and especially inotropes should be strictly avoided. Thus, mechanical circulatory support (MCS) may be considered earlier than in other conditions. There are no prospective studies on the use of MCS in TS patients with shock. Based on clinical experience with MCS devices in cardiogenic shock from other causes and integrating pathophysiological considerations, a proposal for heart failure and MCS management in TS patients is provided in Fig. 4. This proposal emphasizes to identify developing shock early, with the intention to prevent full development of the shock spiral.

Recurrence and long-term risk

The first report on recurrence of TS was published in 2006 in Japanese [123]. In this report, the patient initially had midventricular TS, and subsequent recurrences were midventricular and biventricular apical TS. Later on, several cases with varying types in men and women across all ages were published (Table 7; [124]). One report hypothesized that recurring TS manifests in a different myocardial region than the first episode, i.e., that TS would protect against recurrence in the same region [125]. However, many reports of recurrence in the same region (Table 7) strongly oppose this hypothesis. On the other hand, numerous reports with different TS types in the same patient (Table 7) render the beta-receptor concept of TS development rather unlikely, at least as the only responsible step in pathogenesis. Overall, there is recurrence with all TS types across all ages in men and women, with a mean recurrence rate in adults of around 1.5–2% per year [124]. As extrapolated from case reports, patients with pulmonary triggers from chronic lung disease, with diarrhea or electrolyte disorders, and with drug or substance abuse tend to have a higher chance of recurrence.

Table 7

The spectrum of takotsubo syndrome recurrence

Study	Year	Sex, age at 1st episode	Number of recurrences	First episode	Gap	Second episode	Gap	Third episode	Gap	Fourth episode
Sharath Babu et al.^S41	2019	Female, 59 years	1	Apical	8 months	Apical	–	–	–	–
Napp et al.^S42	2015	Female, 63 years	1	Apical	2 years	Apical	–	–	–	–
Srivastava et al.^S10	2016	Male, 14 years	1	Apical	6 months	Apical	–	–	–	–
Eitel et al.^S43	2014	Female, 96 years	1	Apical	2 years	Midventricular	–	–	–	–
Xu et al.^S44	2014	Female, 52 years	1	Apical	11 years	Midventricular	–	–	–	–
Rashed et al.^S45	2019	Female, 43 years	1	Apical	8 months	Basal	–	–	–	–
Kato et al.^S46	2014	Female, 65 years	1	Midventricular	3 years	Midventricular	–	–	–	–
Wever-Pinzon et al.^S47	2011	Female, 82 years	1	Midventricular	4 months	Apical	–	–	–	–
Blessing et al.^S48	2007	Male, 70 years	1	Basal	3 months	Apical	–	–	–	–
Binaghi et al.^S49	2018	Female, 67 years	1	Basal	≈2 weeks	Apical	–	–	–	–
Piranavan et al.^S50	2019	Female, 66 years	1	Focal	3 years	Midventricular	–	–	–	–
Chandorkar et al.^S51	2014	Male, 28 years	1	RV (apical)	5 months	RV (apical)	–	–	–	–
Joe et al.^S52	2013	Female, 83 years	1	RV (apical)	1 week	Apical	–	–	–	–
Luo et al.^S53	2019	Male, 52 years	1	Biventricular (apical)	2 months	Biventricular (apical)	–	–	–	–
Cattaneo et al.^S54	2015	Male, 66 years	2	Apical	1 year	Apical	2 years	Apical	–	–
Sager et al.^S55	2011	Female, 66 years	2	Midventricular	9 months	Midventricular	3 years	Midventricular	–	–
Shimizu et al.^S56	2006	Male, 60 years	2	Midventricular	2 years	Midventricular	3 months	Biventricular (apical)	–	–
Mugnai et al.^S57	2015	Female, 64 years	2	Apical	8 months	Basal	4 years	Basal	–	–
Rodriguez et al.^S58	2014	Female, 56 years^a	2	Type not reported	Gap not reported	Apical	2 months	Basal	–	–
Ghadri et al.^S59	2012	Female, 65 years	2	Midventricular	8 years	Apical	1 year	Focal	–	–
Opolski et al.^S60	2016	Female, 62 years	3	Apical	10 years	Apical	3 years	Apical	2 years	Apical
Kaushik et al.^S61	2011	Female, 56 years	5	Six episodes of TS over 4 years, with at least one apical and one basal type, suspected to be triggered by cannabis abuse
Chandy and Dawson^S62	2019	Female, 48 years	5	Six episodes of TS over 33 years, with at least two apical types and one focal type

All publications in this table reported recovery of systolic ventricular function between episodes of recurrence

References to the tables are provided as electronic supplementary material

TS takotsubo syndrome

^aAt the time of the second episode

Beyond recurrence, TS also carries a long-term mortality risk [126‐128]. This is probably mainly due to noncardiac causes, and it remains incompletely understood whether long-term risk is due to TS or whether TS occurs in patients already at higher risk due to other causes.

Recently, it was reported that myocardial and systemic inflammation is present in the acute phase of TS and that subtle changes may persist in the heart, in part questioning the concept of transient myocardial dysfunction and recovery [129‐133]. It is indeed not surprising that a cardiac condition that is characterized by severe stunning and significant troponin release evokes an inflammatory response, and that long-term sequelae such as diastolic dysfunction and microscopic fibrosis persist in the myocardium. Although the recent findings are of major importance for a better understanding of the disease, it remains unknown whether they translate into clinical outcomes.

Long-term therapy

TS was initially described as a “stress cardiomyopathy” with an emotional trigger in early years. As outlined above, there is indeed a strong and somehow specific association between the beta-adrenergic system and TS. Interestingly, in an ex vivo model with induced pluripotent stem cell-derived cardiomyocytes from TS patients, there was increased beta-adrenergic activity and response to catecholamines [134], further confirming this association. All this strongly suggests that beta-blockers should be beneficial in TS patients. However, in the InterTAK Registry, 30% of all patients and 60% of patients with recurrent TS were on beta-blockers before TS onset. Most of these were β1-specific. This demonstrates that beta-blockers are not generally sufficient to prevent TS or TS recurrence [4, 124]. In a post hoc analysis of discharge medication, mortality was comparable between TS patients with and without beta-blockers at discharge [4], although this analysis had significant limitations. However, it remains unknown whether a TS episode carries a reduced risk of complications, heart failure, and death in patients on beta-blockers than in patients without. Perhaps the mere blockade of the receptor is not as important as modification of downstream signaling. In summary, although there are many associations, there are no data demonstrating that beta-blocker prescription is of any specific benefit in TS patients. Therefore, beta-blockers should not be given routinely after recovery, unless there is another indication for their use or a study demonstrates a benefit and thereby justifies treatment.

Conclusion

Takotsubo syndrome (TS) occurs in a variety of phenotypes across all ages and genders, and is associated with substantial risk during the acute phase. Mechanical circulatory support is an emerging strategy for patients with TS and shock, in order to avoid catecholamines and inotropes in particular. Prospective studies are needed in this context, as well as for medical treatment of TS with the intention to prevent recurrence.

Compliance with ethical guidelines

Conflict of interest

L.C. Napp: Related to the present work: None. Unrelated to the present work: Modest honoraria for consultancy, proctoring, lectures and travel support from Abiomed, modest honoraria for consultancy, lectures and travel support and research funding from Cytosorbents, modest honoraria for consultancy and travel support from Bayer, modest lecture honoraria from Abbott, Maquet, Orion and Zoll, and travel support from Biotronik, Boston Scientific, Lilly, Medtronic, Merit Medical, Pfizer, Servier, and Volcano. J. Bauersachs: Related to the present work: None. Unrelated to the present work: Honoraria for lectures and/or consulting: Novartis, BMS, Pfizer, Vifor, Bayer, Servier, Orion, CVRx, MSD, Boehringer Ingelheim, AstraZeneca, Abiomed, Abbott, Medtronic; Research support: Zoll, CVRx, Bayer, Vifor, Abiomed, Medtronic.

For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.

Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

Jetzt testen ²

Herz

Print-Titel

Gratisausgabe bestellen ³

Caption Electronic Supplementary Material

Supplementary References to Tables 1–6

Sato H, Tateishi H, Uchida T et al (1990) Takotsubo-type cardiomyopathy due to multivessel spasm. In: Kodama K, Haze K, Hori M (eds) Clinical aspect of myocardial injury: from Ischemia to heart failure. Kagakuhyouronsha Publishing, Tokyo, pp 56–64

Dote K, Sato H, Tateishi H et al (1991) Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases. J Cardiol 21(2):203–214PubMed

Y‑Hassan S, Yamasaki K (2013) History of takotsubo syndrome: is the syndrome really described as a disease entity first in 1990? Some inaccuracies. Int J Cardiol 166(3):736–737. https://doi.org/10.1016/j.ijcard.2012.09.183 CrossRefPubMed

Templin C, Ghadri JR, Diekmann J et al (2015) Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 373(10):929–938. https://doi.org/10.1056/NEJMoa1406761 CrossRefPubMed

Napp LC, Ghadri JR, Bauersachs J, Templin C (2015) Acute coronary syndrome or Takotsubo cardiomyopathy: the suspect may not always be the culprit. Int J Cardiol 187:116–119. https://doi.org/10.1016/j.ijcard.2015.03.255 CrossRefPubMed

Medeiros K, O’Connor MJ, Baicu CF et al (2014) Systolic and diastolic mechanics in stress cardiomyopathy. Circulation 129(16):1659–1667. https://doi.org/10.1161/CIRCULATIONAHA.113.002781 CrossRefPubMed

Ghadri JR, Wittstein IS, Prasad A et al (2018) International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 39(22):2032–2046. https://doi.org/10.1093/eurheartj/ehy076 CrossRefPubMedPubMedCentral

Templin C, Napp LC, Ghadri JR (2016) Takotsubo syndrome: underdiagnosed, underestimated, but understood? J Am Coll Cardiol 67(16):1937–1940. https://doi.org/10.1016/j.jacc.2016.03.006 CrossRefPubMed

Sharkey SW, Pink VR, Lesser JR et al (2015) Clinical profile of patients with high-risk Tako-Tsubo cardiomyopathy. Am J Cardiol 116(5):765–772. https://doi.org/10.1016/j.amjcard.2015.05.054 CrossRefPubMed

10.

Sharkey SW, Lesser JR, Maron MS, Maron BJ (2011) Why not just call it tako-tsubo cardiomyopathy: a discussion of nomenclature. J Am Coll Cardiol 57(13):1496–1497. https://doi.org/10.1016/j.jacc.2010.11.029 CrossRefPubMed

11.

Parodi G (2007) Transient left ventricular apical ballooning—the need for a common terminology. Int J Cardiol 116(3):405. https://doi.org/10.1016/j.ijcard.2006.04.072 CrossRefPubMed

12.

Pelliccia F, Sinagra G, Elliott P et al (2018) Takotsubo is not a cardiomyopathy. Int J Cardiol 254:250–253. https://doi.org/10.1016/j.ijcard.2017.12.009 CrossRefPubMed

13.

Movahed MR (2010) Transient cardiac ballooning is not best nomenclature for Takotsubo cardiomyopathy as it does not capture all variants of this syndrome. Stress cardiomyopathy is a much better term for this syndrome. Clin Cardiol 33(4):241–242. https://doi.org/10.1002/clc.20742 (author reply 242)CrossRefPubMedPubMedCentral

14.

de Gregorio C, Ando G, Trio O (2009) Stress-related left ventricular dysfunction: a common terminology for both Takotsubo-like and neurogenic stress syndromes? J Cardiovasc Med 10(2):204–205. https://doi.org/10.2459/JCM.0b013e32831da953 CrossRef

15.

Pawlowski T, Gil R (2008) Transient left apical ballooning syndrome—the need for a common terminology? A reply. Int J Cardiol 131(1):138–139. https://doi.org/10.1016/j.ijcard.2007.06.099 (author reply 140)CrossRefPubMed

16.

Barriales-Villa R, Hevia S, Santamarta-Liebana E, Moris C (2008) Pheochromocytoma-related cardiomyopathy or stress cardiomyopathy secondary to pheochromocytoma: is new terminology needed? Rev Esp Cardiol 61(4):432–433CrossRef

17.

Patel SM, Lerman A, Lennon RJ, Prasad A (2013) Impaired coronary microvascular reactivity in women with apical ballooning syndrome (Takotsubo/stress cardiomyopathy). Eur Heart J Acute Cardiovasc Care 2(2):147–152. https://doi.org/10.1177/2048872613475891 CrossRefPubMedPubMedCentral

18.

Wittstein IS, Thiemann DR, Lima JA et al (2005) Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 352(6):539–548. https://doi.org/10.1056/NEJMoa043046 CrossRefPubMed

19.

Y‑Hassan S, Henareh L (2015) Plasma catecholamine levels in patients with takotsubo syndrome: Implications for the pathogenesis of the disease. Int J Cardiol 181:35–38. https://doi.org/10.1016/j.ijcard.2014.11.149 CrossRefPubMed

20.

Madhavan M, Borlaug BA, Lerman A et al (2009) Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy): insights into the clinical significance of B‑type natriuretic peptide and troponin levels. Heart 95(17):1436–1441. https://doi.org/10.1136/hrt.2009.170399 CrossRefPubMed

21.

Marfella R, Barbieri M, Sardu C et al (2016) Effects of alpha-lipoic acid therapy on sympathetic heart innervation in patients with previous experience of transient takotsubo cardiomyopathy. J Cardiol 67(2):153–161. https://doi.org/10.1016/j.jjcc.2015.07.012 CrossRefPubMed

22.

Y‑Hassan S (2015) The causal link between the blood borne catecholamines and takotsubo syndrome: too many flaws. Int J Cardiol 189:194–195. https://doi.org/10.1016/j.ijcard.2015.04.075 CrossRefPubMed

23.

Abraham J, Mudd JO, Kapur NK et al (2009) Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol 53(15):1320–1325. https://doi.org/10.1016/j.jacc.2009.02.020 CrossRefPubMed

24.

Bybee KA, Kara T, Prasad A et al (2004) Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med 141(11):858–865. https://doi.org/10.7326/0003-4819-141-11-200412070-00010 CrossRefPubMed

25.

Prasad A, Lerman A, Rihal CS (2008) Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J 155(3):408–417. https://doi.org/10.1016/j.ahj.2007.11.008 CrossRefPubMed

26.

Paur H, Wright PT, Sikkel MB et al (2012) High levels of circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 126(6):697–706. https://doi.org/10.1161/CIRCULATIONAHA.112.111591 CrossRefPubMedPubMedCentral

27.

Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P et al (2011) Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 306(3):277–286. https://doi.org/10.1001/jama.2011.992 CrossRefPubMed

28.

Braunwald E, Kloner RA (1982) The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 66(6):1146–1149CrossRef

29.

Albert CL, White KT, Cremer PC, Jaber WA (2019) Stress for a stressed out heart: classic cardiac PET findings in takotsubo cardiomyopathy. J Nucl Cardiol 26(2):679–680. https://doi.org/10.1007/s12350-018-1306-8 CrossRefPubMed

30.

Ekenbäck C, Tornvall P, Spaak J (2019) Takotsubo twins. BMJ Case Rep. https://doi.org/10.1136/bcr-2018-227885 CrossRefPubMed

31.

Sharkey SW, Lips DL, Pink VR, Maron BJ (2013) Daughter-mother tako-tsubo cardiomyopathy. Am J Cardiol 112(1):137–138. https://doi.org/10.1016/j.amjcard.2013.02.063 CrossRefPubMed

32.

Limongelli G, Masarone D, Maddaloni V et al (2016) Genetics of Takotsubo syndrome. Heart Fail Clin 12(4):499–506. https://doi.org/10.1016/j.hfc.2016.06.007 CrossRefPubMed

33.

Eitel I, Möller C, Munz M et al (2017) Genome-wide association study in takotsubo syndrome—Preliminary results and future directions. Int J Cardiol 236:335–339. https://doi.org/10.1016/j.ijcard.2017.01.093 CrossRefPubMed

34.

Handy AD, Prasad A, Olson TM (2009) Investigating genetic variation of adrenergic receptors in familial stress cardiomyopathy (apical ballooning syndrome). J Cardiol 54(3):516–517. https://doi.org/10.1016/j.jjcc.2009.08.008 CrossRefPubMed

35.

Lacey CJ, Doudney K, Bridgman PG et al (2018) Copy number variants implicate cardiac function and development pathways in earthquake-induced stress cardiomyopathy. Sci Rep 8(1):7548. https://doi.org/10.1038/s41598-018-25827-5 CrossRefPubMedPubMedCentral

36.

Schultz T, Shao Y, Redfors B et al (2012) Stress-induced cardiomyopathy in Sweden: evidence for different ethnic predisposition and altered cardio-circulatory status. Cardiology 122(3):180–186. https://doi.org/10.1159/000338814 CrossRefPubMed

37.

Spinelli L, Trimarco V, Di Marino S et al (2010) L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome. Eur J Heart Fail 12(1):13–16. https://doi.org/10.1093/eurjhf/hfp173 CrossRefPubMed

38.

Vriz O, Minisini R, Citro R et al (2011) Analysis of beta1 and beta2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy. Acta Cardiol 66(6):787–790. https://doi.org/10.1080/ac.66.6.2136964 CrossRefPubMed

39.

Sharkey SW, Maron BJ, Nelson P et al (2009) Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol 53(1):53–57. https://doi.org/10.1016/j.jjcc.2008.08.006 CrossRefPubMed

40.

Ueyama T, Ishikura F, Matsuda A et al (2007) Chronic estrogen supplementation following ovariectomy improves the emotional stress-induced cardiovascular responses by indirect action on the nervous system and by direct action on the heart. Circ J 71(4):565–573. https://doi.org/10.1253/circj.71.565 CrossRefPubMed

41.

Ueyama T, Kasamatsu K, Hano T et al (2008) Catecholamines and estrogen are involved in the pathogenesis of emotional stress-induced acute heart attack. Ann N Y Acad Sci 1148:479–485. https://doi.org/10.1196/annals.1410.079 CrossRefPubMed

42.

Sugimoto K, Inamasu J, Hirose Y et al (2012) The role of norepinephrine and estradiol in the pathogenesis of cardiac wall motion abnormality associated with subarachnoid hemorrhage. Stroke 43(7):1897–1903. https://doi.org/10.1161/STROKEAHA.111.646893 CrossRefPubMed

43.

El-Battrawy I, Zhao Z, Lan H et al (2018) Estradiol protection against toxic effects of catecholamine on electrical properties in human-induced pluripotent stem cell derived cardiomyocytes. Int J Cardiol 254:195–202. https://doi.org/10.1016/j.ijcard.2017.11.007 CrossRefPubMed

44.

Möller C, Stiermaier T, Brabant G et al (2018) Comprehensive assessment of sex hormones in Takotsubo syndrome. Int J Cardiol 250:11–15. https://doi.org/10.1016/j.ijcard.2017.10.047 CrossRefPubMed

45.

Brenner R, Weilenmann D, Maeder MT et al (2012) Clinical characteristics, sex hormones, and long-term follow-up in Swiss postmenopausal women presenting with Takotsubo cardiomyopathy. Clin Cardiol 35(6):340–347. https://doi.org/10.1002/clc.21986 CrossRefPubMedPubMedCentral

46.

Kakinuma Y, Okada S, Nogami M, Kumon Y (2013) The human female heart incorporates glucose more efficiently than the male heart. Int J Cardiol 168(3):2518–2521. https://doi.org/10.1016/j.ijcard.2013.03.016 CrossRefPubMed

47.

Templin C, Hanggi J, Klein C et al (2019) Altered limbic and autonomic processing supports brain-heart axis in Takotsubo syndrome. Eur Heart J 40(15):1183–1187. https://doi.org/10.1093/eurheartj/ehz068 CrossRefPubMedPubMedCentral

48.

Behnes M, Baumann S, Borggrefe M, Haghi D (2013) Biventricular takotsubo cardiomyopathy in a heart transplant recipient. Circulation 128(5):e62–e63. https://doi.org/10.1161/CIRCULATIONAHA.113.001519 CrossRefPubMed

49.

Chinali M, Formigari R, Grutter G (2018) Takotsubo cardiomyopathy in a young adult with transplanted heart: what happened to denervation? ESC Heart Fail 5(1):197–200. https://doi.org/10.1002/ehf2.12242 CrossRefPubMedPubMedCentral

50.

Itzhaki Ben ZO, Ben-Avraham B, Hamdan A et al (2019) A rare case of Takotsubo syndrome in a patient 5 months after heart transplantation. Heart Fail. https://doi.org/10.1002/ehf2.12575 CrossRef

51.

Hernandez LE (2014) Takotsubo cardiomyopathy: how much do we know of this syndrome in children and young adults? Cardiol Young 24(4):580–592. https://doi.org/10.1017/S1047951114000080 CrossRefPubMed

52.

Ghadri JR, Sarcon A, Diekmann J et al (2016) Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. Eur Heart J 37(37):2823–2829. https://doi.org/10.1093/eurheartj/ehv757 CrossRefPubMedPubMedCentral

53.

Schlossbauer SA, Ghadri JR, Templin C (2016) Takotsubo-Syndrom – ein häufig verkanntes Krankheitsbild. Praxis 105(20):1185–1192. https://doi.org/10.1024/1661-8157/a002434 CrossRefPubMed

54.

Sharkey SW, Windenburg DC, Lesser JR et al (2010) Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol 55(4):333–341. https://doi.org/10.1016/j.jacc.2009.08.057 CrossRefPubMed

55.

Y‑Hassan S, Feldt K, Stalberg M (2015) A missed penalty kick triggered coronary death in the husband and broken heart syndrome in the wife. Am J Cardiol 116(10):1639–1642. https://doi.org/10.1016/j.amjcard.2015.08.033 CrossRefPubMed

56.

Compare A, Bigi R, Orrego PS et al (2013) Type D personality is associated with the development of stress cardiomyopathy following emotional triggers. Ann Behav Med 45(3):299–307. https://doi.org/10.1007/s12160-013-9474-x CrossRefPubMed

57.

Bill V, El-Battrawy I, Schramm K et al (2017) Coincidental coronary artery disease impairs outcome in patients with takotsubo cardiomyopathy. QJM 110(8):483–488. https://doi.org/10.1093/qjmed/hcx035 CrossRefPubMed

58.

Haghi D, Roehm S, Hamm K et al (2010) Takotsubo cardiomyopathy is not due to plaque rupture: an intravascular ultrasound study. Clin Cardiol 33(5):307–310. https://doi.org/10.1002/clc.20747 CrossRefPubMedPubMedCentral

59.

Hoyt J, Lerman A, Lennon RJ et al (2010) Left anterior descending artery length and coronary atherosclerosis in apical ballooning syndrome (Takotsubo/stress induced cardiomyopathy). Int J Cardiol 145(1):112–115. https://doi.org/10.1016/j.ijcard.2009.06.018 CrossRefPubMed

60.

Kurisu S, Inoue I, Kawagoe T et al (2009) Prevalence of incidental coronary artery disease in tako-tsubo cardiomyopathy. Coron Artery Dis 20(3):214–218. https://doi.org/10.1097/MCA.0b013e3283299260 CrossRefPubMed

61.

Parodi G, Citro R, Bellandi B, Del Pace S, Rigo F, Marrani M, Provenza G, Leoncini M, Salerno Uriarte JA, Bovenzi F, Bossone E, Tako-tsubo Italian N (2013) Tako-tsubo cardiomyopathy and coronary artery disease: a possible association. Coron Artery Dis 24(6):527–533. https://doi.org/10.1097/MCA.0b013e3283645c4e CrossRefPubMed

62.

Winchester DE, Ragosta M, Taylor AM (2008) Concurrence of angiographic coronary artery disease in patients with apical ballooning syndrome (tako-tsubo cardiomyopathy). Catheter Cardiovasc Interv 72(5):612–616. https://doi.org/10.1002/ccd.21738 CrossRefPubMed

63.

Delgado GA, Truesdell AG, Kirchner RM et al (2011) An angiographic and intravascular ultrasound study of the left anterior descending coronary artery in takotsubo cardiomyopathy. Am J Cardiol 108(6):888–891. https://doi.org/10.1016/j.amjcard.2011.05.012 CrossRefPubMed

64.

Eitel I, Stiermaier T, Graf T et al (2016) Optical coherence tomography to evaluate plaque burden and morphology in patients with Takotsubo syndrome. J Am Heart Assoc. https://doi.org/10.1161/JAHA.116.004474 CrossRefPubMedPubMedCentral

65.

Pawlowski T, Mintz GS, Kulawik T, Gil RJ (2010) Virtual histology intravascular ultrasound evaluation of the left anterior descending coronary artery in patients with transient left ventricular ballooning syndrome. Kardiol Pol 68(10):1093–1098PubMed

66.

Abreu G, Rocha S, Bettencourt N et al (2016) An unusual trigger causing Takotsubo Syndrome. Int J Cardiol 223:118–120. https://doi.org/10.1016/j.ijcard.2016.08.162 CrossRefPubMed

67.

Angulo-Llanos R, Sanz-Ruiz R, Solis J, Fernandez-Aviles F (2013) Acute myocardial infarction: an uncommon complication of takotsubo cardiomyopathy. Catheter Cardiovasc Interv 82(6):909–913. https://doi.org/10.1002/ccd.24846 CrossRefPubMed

68.

Mele M, Martimucci M, Maggi A et al (2015) Cardioembolic acute myocardial infarction associated with apical ballooning: considerations. Int J Cardiol 192:16–17. https://doi.org/10.1016/j.ijcard.2015.05.025 CrossRefPubMed

69.

Sharkey SW, Kalra A, Henry TD et al (2019) Coexistence of acute takotsubo syndrome and acute coronary syndrome. Catheter Cardiovasc Interv. https://doi.org/10.1002/ccd.28595 CrossRefPubMed

70.

Tota F, Ruggiero M, Sassara M et al (2013) Subacute stent thrombosis and stress-induced cardiomyopathy: trigger or consequence? Am J Cardiovasc Dis 3(3):175–179PubMedPubMedCentral

71.

Y‑Hassan S (2015) Takotsubo syndrome triggered by acute coronary syndrome in a cohort of 20 patients: an often missed diagnosis. Int J Cardiol 2(2):28–33. https://doi.org/10.19070/2470-4563-150007 CrossRef

72.

Redfors B, Ramunddal T, Shao Y, Omerovic E (2014) Takotsubo triggered by acute myocardial infarction: a common but overlooked syndrome? J Geriatr Cardiol 11(2):171–173. https://doi.org/10.3969/j.issn.1671-5411.2014.02.001 CrossRefPubMedPubMedCentral

73.

Arcari L, Limite LR, Cacciotti L et al (2017) Tortuosity, recurrent segments, and bridging of the epicardial coronary arteries in patients with the takotsubo syndrome. Am J Cardiol 119(2):243–248. https://doi.org/10.1016/j.amjcard.2016.09.055 CrossRefPubMed

74.

Khalid N, Iqbal I, Ikram A (2013) Thrombolysis in myocardial infarction frame count in Takotsubo cardiomyopathy. J Am Coll Cardiol 61(10 Supplement):E50. https://doi.org/10.1016/s0735-1097(13)60051-0 CrossRef

75.

Galiuto L, De Caterina AR, Porfidia A et al (2010) Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in Apical Ballooning or Tako-Tsubo Syndrome. Eur Heart J 31(11):1319–1327. https://doi.org/10.1093/eurheartj/ehq039 CrossRefPubMed

76.

Loffi M, Santangelo A, Kozel M et al (2018) Takotsubo cardiomyopathy: one more Angiographic evidence of microvascular dysfunction. Biomed Res Int. https://doi.org/10.1155/2018/5281485 CrossRefPubMedPubMedCentral

77.

Montone RA, Galiuto L, Meucci MC et al (2020) Coronary slow flow is associated with a worse clinical outcome in patients with Takotsubo syndrome. Heart. https://doi.org/10.1136/heartjnl-2019-315909 CrossRefPubMed

78.

Redfors B, Shao Y, Lyon AR, Omerovic E (2014) Diagnostic criteria for takotsubo syndrome: a call for consensus. Int J Cardiol 176(1):274–276. https://doi.org/10.1016/j.ijcard.2014.06.094 CrossRefPubMed

79.

Scantlebury DC, Prasad A (2014) Diagnosis of Takotsubo cardiomyopathy. Circ J 78(9):2129–2139. https://doi.org/10.1253/circj.cj-14-0859 CrossRefPubMed

80.

Y‑Hassan S (2014) Too many cooks spoil the broth: the currently existing diagnostic criteria for Takotsubo syndrome. Int J Cardiol 173(3):568–570. https://doi.org/10.1016/j.ijcard.2014.03.119 CrossRefPubMed

81.

Lyon AR, Bossone E, Schneider B et al (2016) Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo syndrome of the heart failure association of the European society of cardiology. Eur J Heart Fail 18(1):8–27. https://doi.org/10.1002/ejhf.424 CrossRefPubMed

82.

Citro R, Lyon AR, Meimoun P et al (2015) Standard and advanced echocardiography in takotsubo (stress) cardiomyopathy: clinical and prognostic implications. J Am Soc Echocardiogr 28(1):57–74. https://doi.org/10.1016/j.echo.2014.08.020 CrossRefPubMed

83.

Ibanez B, James S, Agewall S et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393 CrossRefPubMed

84.

Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267–315. https://doi.org/10.1093/eurheartj/ehv320 CrossRefPubMed

85.

Patel SM, Lennon RJ, Prasad A (2012) Regional wall motion abnormality in apical ballooning syndrome (Takotsubo/stress cardiomyopathy): importance of biplane left ventriculography for differentiating from spontaneously aborted anterior myocardial infarction. Int J Cardiovasc Imaging 28(4):687–694. https://doi.org/10.1007/s10554-011-9911-5 CrossRefPubMed

86.

Eitel I, Lucke C, Behrendt F et al (2010) Full recovery of Takotsubo cardiomyopathy (apical ballooning) in two days. Int J Cardiol 143(3):e51–e53. https://doi.org/10.1016/j.ijcard.2008.12.044 CrossRefPubMed

87.

Lyon AR, Akashi YJ (2015) Use of cardiac MRI to diagnose Takotsubo syndrome. Nat Rev Cardiol 12(11):669. https://doi.org/10.1038/nrcardio.2015.155 CrossRefPubMed

88.

Assomull RG, Lyne JC, Keenan N et al (2007) The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J 28(10):1242–1249. https://doi.org/10.1093/eurheartj/ehm113 CrossRefPubMed

89.

Gerbaud E, Montaudon M, Leroux L et al (2008) MRI for the diagnosis of left ventricular apical ballooning syndrome (LVABS). Eur Radiol 18(5):947–954. https://doi.org/10.1007/s00330-008-0853-9 CrossRefPubMed

90.

Mitchell JH, Hadden TB, Wilson JM et al (2007) Clinical features and usefulness of cardiac magnetic resonance imaging in assessing myocardial viability and prognosis in Takotsubo cardiomyopathy (transient left ventricular apical ballooning syndrome). Am J Cardiol 100(2):296–301. https://doi.org/10.1016/j.amjcard.2007.02.091 CrossRefPubMed

91.

Prasad A, Dangas G, Srinivasan M et al (2014) Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: an analysis from a multicenter, international study of ST-elevation myocardial infarction. Catheter Cardiovasc Interv 83(3):343–348. https://doi.org/10.1002/ccd.23441 CrossRefPubMed

92.

Madias JE (2014) Pulmonary embolism and Takotsubo syndrome in tandem: an interplay of pathologies needing our vigilance. Heart Lung 43(2):168. https://doi.org/10.1016/j.hrtlng.2014.01.003 CrossRefPubMed

93.

Toni C, Iannaccone F, Chella P et al (2019) Sudden death in a case of recurrent Takotsubo syndrome. Forensic Sci Med Pathol. https://doi.org/10.1007/s12024-019-00163-w CrossRefPubMed

94.

Indorato F, Bartoloni G (2016) Post-mortem Takotsubo cardiomyopathy diagnosis: the challenge is open! Forensic Sci Med Pathol 12(2):227–228. https://doi.org/10.1007/s12024-016-9759-z CrossRefPubMed

95.

Oras J, Lundgren J, Redfors B et al (2017) Takotsubo syndrome in hemodynamically unstable patients admitted to the intensive care unit—a retrospective study. Acta Anaesthesiol Scand 61(8):914–924. https://doi.org/10.1111/aas.12940 CrossRefPubMed

96.

Park JH, Kang SJ, Song JK et al (2005) Left ventricular apical ballooning due to severe physical stress in patients admitted to the medical ICU. Chest 128(1):296–302. https://doi.org/10.1378/chest.128.1.296 CrossRefPubMed

97.

Rowell AC, Stedman WG, Janin PF et al (2019) Silent left ventricular apical ballooning and Takotsubo cardiomyopathy in an Australian intensive care unit. ESC Heart Fail. https://doi.org/10.1002/ehf2.12517 CrossRefPubMedPubMedCentral

98.

Champion S, Belcour D, Vandroux D et al (2015) Stress (Tako-tsubo) cardiomyopathy in critically-ill patients. Eur Heart J Acute Cardiovasc Care 4(2):189–196. https://doi.org/10.1177/2048872614547686 CrossRefPubMed

99.

Desmet W, Bennett J, Ferdinande B et al (2014) The apical nipple sign: a useful tool for discriminating between anterior infarction and transient left ventricular ballooning syndrome. Eur Heart J Acute Cardiovasc Care 3(3):264–267. https://doi.org/10.1177/2048872613517359 CrossRefPubMed

100.

Haghi D, Papavassiliu T, Fluchter S et al (2006) Variant form of the acute apical ballooning syndrome (takotsubo cardiomyopathy): observations on a novel entity. Heart 92(3):392–394. https://doi.org/10.1136/hrt.2005.061044 CrossRefPubMedPubMedCentral

101.

Hurst RT, Askew JW, Reuss CS et al (2006) Transient midventricular ballooning syndrome: a new variant. J Am Coll Cardiol 48(3):579–583. https://doi.org/10.1016/j.jacc.2006.06.015 CrossRefPubMed

102.

Robles P, Monedero I, Rubio A, Botas J (2015) Reverse or inverted apical ballooning in a case of refeeding syndrome. World J Cardiol 7(6):361–366. https://doi.org/10.4330/wjc.v7.i6.361 CrossRefPubMedPubMedCentral

103.

Yasu T, Tone K, Kubo N, Saito M (2006) Transient mid-ventricular ballooning cardiomyopathy: a new entity of Takotsubo cardiomyopathy. Int J Cardiol 110(1):100–101. https://doi.org/10.1016/j.ijcard.2005.05.060 CrossRefPubMed

104.

Kato K, Kitahara H, Fujimoto Y et al (2016) Prevalence and clinical features of focal Takotsubo cardiomyopathy. Circ J 80(8):1824–1829. https://doi.org/10.1253/circj.CJ-16-0360 CrossRefPubMed

105.

Bonnemeier H, Ortak J, Burgdorf C et al (2007) “The artichoke heart”: the inverse counterpart of left ventricular apical ballooning. Resuscitation 72(3):342–343. https://doi.org/10.1016/j.resuscitation.2006.07.008 CrossRefPubMed

106.

Cacciotti L, Camastra GS, Musaro S et al (2010) Stress cardiomyopathy: transient basal ballooning. J Cardiovasc Med 11(10):764–767. https://doi.org/10.2459/JCM.0b013e328334466c CrossRef

107.

Phanthawimol W, Ito H, Fukuyama O (2009) A case with transient anterolateral wall ballooning syndrome; new variant form of Takotsubo cardiomyopathy? Hawaii Med J 68(10):249–252PubMed

108.

Rognoni A, Bertolazzi M, Maccio S et al (2009) Unusual case of left ventricular ballooning involving the inferior wall: a case report. Cases J 2(1):140. https://doi.org/10.1186/1757-1626-2-140 CrossRefPubMedPubMedCentral

109.

Ghadri JR, Cammann VL, Napp LC et al (2016) Differences in the clinical profile and outcomes of typical and atypical Takotsubo syndrome: data from the international Takotsubo registry. JAMA Cardiol 1(3):335–340. https://doi.org/10.1001/jamacardio.2016.0225 CrossRefPubMed

110.

Bridgman PG, Chan CW (2017) The fifth takotsubo variant. Echocardiography 34(1):122–123. https://doi.org/10.1111/echo.13405 CrossRefPubMed

111.

Kagiyama N, Okura H, Kume T et al (2015) Isolated right ventricular takotsubo cardiomyopathy. Eur Heart J Cardiovasc Imaging 16(3):285. https://doi.org/10.1093/ehjci/jeu207 CrossRefPubMed

112.

Staehli BE, Ruschitzka F, Enseleit F (2011) Isolated right ventricular ballooning syndrome: a new variant of transient cardiomyopathy. Eur Heart J 32(14):1821. https://doi.org/10.1093/eurheartj/ehr079 CrossRef

113.

Sumida H, Morihisa K, Katahira K et al (2017) Isolated right ventricular stress (Takotsubo) cardiomyopathy. Intern Med 56(16):2159–2164. https://doi.org/10.2169/internalmedicine.8323-16 CrossRefPubMedPubMedCentral

114.

Elesber AA, Prasad A, Bybee KA et al (2006) Transient cardiac apical ballooning syndrome: prevalence and clinical implications of right ventricular involvement. J Am Coll Cardiol 47(5):1082–1083. https://doi.org/10.1016/j.jacc.2005.12.004 CrossRefPubMed

115.

Almendro-Delia M, Nunez-Gil IJ, Lobo M et al (2018) Short- and long-term prognostic relevance of cardiogenic shock in Takotsubo syndrome: results from the RETAKO registry. JACC Heart Fail 6(11):928–936. https://doi.org/10.1016/j.jchf.2018.05.015 CrossRefPubMed

116.

Santoro F, Nunez GIJ, Stiermaier T et al (2019) Assessment of the German and Italian stress cardiomyopathy score for risk stratification for in-hospital complications in patients with Takotsubo syndrome. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2019.2597 CrossRefPubMed

117.

Nunez-Gil IJ, Almendro-Delia M, Andres M et al (2016) Secondary forms of Takotsubo cardiomyopathy: a whole different prognosis. Eur Heart J Acute Cardiovasc Care 5(4):308–316. https://doi.org/10.1177/2048872615589512 CrossRefPubMed

118.

Isogai T, Yasunaga H, Matsui H et al (2014) Out-of-hospital versus in-hospital Takotsubo cardiomyopathy: analysis of 3719 patients in the diagnosis procedure combination database in Japan. Int J Cardiol 176(2):413–417. https://doi.org/10.1016/j.ijcard.2014.07.110 CrossRefPubMed

119.

Redfors B, Vedad R, Angeras O et al (2015) Mortality in takotsubo syndrome is similar to mortality in myocardial infarction—a report from the SWEDEHEART registry. Int J Cardiol 185:282–289. https://doi.org/10.1016/j.ijcard.2015.03.162 CrossRefPubMed

120.

Nascimento FO, Krishna RK, Hrachian H, Santana O (2013) Wearable cardioverter defibrillator in stress cardiomyopathy and cardiac arrest. BMJ Case Rep. https://doi.org/10.1136/bcr-2013-009789 CrossRefPubMedPubMedCentral

121.

Peters S, Klein HU (2012) WCD LifeVest: risk stratification in a case of Tako-Tsubo cardiomyopathy with QT interval prolongation. Herz 37(2):219–221. https://doi.org/10.1007/s00059-011-3440-9 CrossRefPubMed

122.

Rigamonti E, Antiochios P, Vincenti MG et al (2019) Suspected Takotsubo syndrome recurrence and asymptomatic malignant ventricular arrhythmias: the possible role of wearable cardioverter defibrillators. J Cardiovasc Med. https://doi.org/10.2459/JCM.0000000000000878 CrossRef

123.

Shimizu M, Kato Y, Masai H et al (2006) Recurrent episodes of takotsubo-like transient left ventricular ballooning occurring in different regions: a case report. J Cardiol 48(2):101–107PubMed

124.

Kato K, Di Vece D, Cammann VL et al (2019) Takotsubo recurrence: morphological types and triggers and identification of risk factors. J Am Coll Cardiol 73(8):982–984. https://doi.org/10.1016/j.jacc.2018.12.033 CrossRefPubMed

125.

Xu B, Williams PD, Brown M, Macisaac A (2014) Takotsubo cardiomyopathy: does recurrence tend to occur in a previously unaffected ventricular wall region? Circulation 129(7):e339–e340. https://doi.org/10.1161/CIRCULATIONAHA.113.007015 CrossRefPubMed

126.

Ghadri JR, Kato K, Cammann VL et al (2018) Long-term prognosis of patients with Takotsubo syndrome. J Am Coll Cardiol 72(8):874–882. https://doi.org/10.1016/j.jacc.2018.06.016 CrossRefPubMed

127.

Napp LC (2019) The risk of Takotsubo syndrome: seeing the light. JACC Heart Fail 7(2):155–157. https://doi.org/10.1016/j.jchf.2018.11.012 CrossRefPubMed

128.

Pelliccia F, Pasceri V, Patti G et al (2019) Long-term prognosis and outcome predictors in Takotsubo syndrome: a systematic review and meta-regression study. JACC Heart Fail 7(2):143–154. https://doi.org/10.1016/j.jchf.2018.10.009 CrossRefPubMed

129.

Dawson DK (2018) Takotsubo: the myth of rapid and complete recovery. Eur Heart J 39(42):3762–3763. https://doi.org/10.1093/eurheartj/ehy660 CrossRefPubMed

130.

Scally C, Abbas H, Ahearn T et al (2019) Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. Circulation 139(13):1581–1592. https://doi.org/10.1161/CIRCULATIONAHA.118.037975 CrossRefPubMedPubMedCentral

131.

Scally C, Rudd A, Mezincescu A et al (2018) Persistent long-term structural, functional, and metabolic changes after stress-induced (Takotsubo) cardiomyopathy. Circulation 137(10):1039–1048. https://doi.org/10.1161/CIRCULATIONAHA.117.031841 CrossRefPubMedPubMedCentral

132.

Schwarz K, Ahearn T, Srinivasan J et al (2017) Alterations in cardiac deformation, timing of contraction and relaxation, and early myocardial fibrosis accompany the apparent recovery of acute stress-induced (Takotsubo) Cardiomyopathy: an end to the concept of transience. J Am Soc Echocardiogr 30(8):745–755. https://doi.org/10.1016/j.echo.2017.03.016 CrossRefPubMed

133.

Wilson HM, Cheyne L, Brown PAJ et al (2018) Characterization of the myocardial inflammatory response in acute stress-induced (Takotsubo) cardiomyopathy. JACC Basic Transl Sci 3(6):766–778. https://doi.org/10.1016/j.jacbts.2018.08.006 CrossRefPubMedPubMedCentral

134.

Borchert T, Hubscher D, Guessoum CI et al (2017) Catecholamine-dependent beta-adrenergic signaling in a pluripotent stem cell model of Takotsubo cardiomyopathy. J Am Coll Cardiol 70(8):975–991. https://doi.org/10.1016/j.jacc.2017.06.061 CrossRefPubMed

135.

Corlan AD (2019) Medline trend: automated yearly statistics of PubMed results for any query, 2004. http://dan.corlan.net/medline-trend.html. Accessed 27 Dec 2019

136.

Baran DA, Grines CL, Bailey S et al (2019) SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 94(1):29–37. https://doi.org/10.1002/ccd.28329 CrossRefPubMed

137.

Jentzer JC, van Diepen S, Barsness GW et al (2019) Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol 74(17):2117–2128. https://doi.org/10.1016/j.jacc.2019.07.077 CrossRefPubMed

Titel: Takotsubo syndrome: between evidence, myths, and misunderstandings
verfasst von: L. Christian Napp, MD
Johann Bauersachs, MD, FESC, FHFA, FAHA
Publikationsdatum: 23.03.2020
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 3/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-020-04906-2

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Takotsubo syndrome: between evidence, myths, and misunderstandings

Abstract

Electronic supplementary material

Nomenclature

Spasm, catecholamines, gender, and the brain

Age and trigger

Coexisting coronary artery disease

How to diagnose Takotsubo syndrome

Incidence

Types of TS

In-hospital complications

Recurrence and long-term risk

Long-term therapy

Conclusion

Compliance with ethical guidelines

Conflict of interest

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

Herz

Caption Electronic Supplementary Material

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Electronic supplementary material

Nomenclature

Spasm, catecholamines, gender, and the brain

Age and trigger

Coexisting coronary artery disease

How to diagnose Takotsubo syndrome

Incidence

Types of TS

In-hospital complications

Recurrence and long-term risk

Long-term therapy

Conclusion

Compliance with ethical guidelines

Conflict of interest

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

Herz

Caption Electronic Supplementary Material

Weitere Artikel der Ausgabe 3/2020

Arrhythmogenic right ventricular cardiomyopathy

Myocardial reperfusion with tirofiban injection via aspiration catheter

SARS-CoV-2: a potential novel etiology of fulminant myocarditis

Epicardial adipose tissue: good or bad for cardiac function?

The German CPU registry: Comparison of smokers and nonsmokers

Dilated cardiomyopathies and non-compaction cardiomyopathy

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie